| Literature DB >> 24566820 |
Erin O'Carrol Bantum1, Cheryl L Albright, Kami K White, Jeffrey L Berenberg, Gabriela Layi, Phillip L Ritter, Diana Laurent, Katy Plant, Kate Lorig.
Abstract
BACKGROUND: Given the substantial improvements in cancer screening and cancer treatment in the United States, millions of adult cancer survivors live for years following their initial cancer diagnosis and treatment. However, latent side effects can occur and some symptoms can be alleviated or managed effectively via changes in lifestyle behaviors.Entities:
Keywords: cancer survivors; online interventions; social support
Mesh:
Year: 2014 PMID: 24566820 PMCID: PMC3961702 DOI: 10.2196/jmir.3020
Source DB: PubMed Journal: J Med Internet Res ISSN: 1438-8871 Impact factor: 5.428
Figure 1Topics included in the Surviving and Thriving with Cancer Intervention.
Figure 2CONSORT recruitment diagram.
Baseline characteristics of study population.
| Characteristic | Control group, | Intervention group, |
| |
| Age, mean (SD) |
| 49.3 (11.0) | 52.4 (11.0) | .008 |
| Female |
| 148 (84.1) | 141 (80.1) | .33 |
|
| .84 | |||
|
| Caucasian | 150 (85.2) | 157 (89.2) |
|
|
| Asian | 9 (5.1) | 8 (4.6) |
|
|
| African American | 4 (2.3) | 2 (1.1) |
|
|
| American Indian/Alaskan Native | 3 (1.7) | 2 (1.1) |
|
|
| Native Hawaiian/Pacific Islander | 3 (1.7) | 1 (0.6) |
|
|
| Other | 7 (4.0) | 6 (3.4) |
|
| Married |
| 122 (69.3) | 109 (61.9) | .14 |
| Highest year education attained, mean (SD) | 16.5 (3.1) | 16.3 (2.8) | .62 | |
|
| .43 | |||
|
| Current | 4 (2.3) | 7 (4.0) |
|
|
| Former | 57 (32.4) | 64 (36.4) |
|
|
| Never | 115 (65.3) | 105 (59.7) |
|
|
| .70 | |||
|
| Breast | 84 (47.7) | 83 (47.2) |
|
|
| Endometrium/Uterine/Ovarian | 23 (13.1) | 22 (12.5) |
|
|
| Non-Hodgkins Lymphoma | 13 (7.4) | 7 (4.0) |
|
|
| Colorectal | 11 (6.5) | 11 (6.5) |
|
|
| Lung | 7 (4.0) | 8 (4.6) |
|
|
| Thyroid | 6 (3.4) | 8 (4.6) |
|
|
| Oral | 6 (3.4) | 5 (2.8) |
|
|
| .96 | |||
|
| In situ | 9 (5.1) | 7 (4.0) |
|
|
| Stage 1 | 45 (25.6) | 45 (25.6) |
|
|
| Stage 2 | 52 (29.6) | 55 (31.3) |
|
|
| Stage 3 | 37 (21.0) | 41 (23.3) |
|
|
| Stage 4 | 16 (9.1) | 13 (7.4) |
|
|
| Unknown | 17 (9.7) | 15 (8.5) |
|
| Number of years since cancer diagnosed, mean (SD) | 2.5 (1.3) | 2.4 (1.4) | .41 | |
| Number of years since treatment completed, mean (SD) | 1.9 (1.2) | 1.7 (1.2) | .09 | |
|
| ||||
|
| High blood pressure | 31 (17.6) | 34 (19.3) | .68 |
|
| Depression | 32 (18.2) | 29 (16.5) | .67 |
|
| Back pain | 25 (14.2) | 29 (16.5) | .55 |
|
| Anxiety | 29 (16.5) | 23 (13.1) | .37 |
|
| Arthritis | 18 (10.2) | 27 (15.3) | .15 |
|
| Sleep disorder | 18 (10.2) | 12 (6.8) | .25 |
|
| Asthma | 13 (7.4) | 13 (7.4) | 1.0 |
|
| Diabetes | 9 (5.1) | 11 (6.3) | .65 |
|
| Heart disease | 3 (1.7) | 8 (4.6) | .13 |
|
| Emphysema, COPD, chronic bronchitis | 3 (1.7) | 5 (2.8) | .72 |
|
| Other | 39 (22.2) | 39 (22.2) | 1.0 |
aSites also reported were oral cavity (n=11), soft tissue (n=11), testicular (n=10), kidney and renal (n=10), and other [n=26, including brain (n=5), prostate (n=4), eye (n=3)].
Mean (95% CI)a of outcome measures from baseline to 6 months by condition group.
| Outcome measures | Control group, mean (95% CI) | Intervention group, mean (95% CI) |
| Effect size | ||
| Baseline | Month 6 | Baseline | Month 6 |
|
| |
| Fatigue (BFId) | 40.8 (38.9-42.8) | 40.7 (38.7-42.8) | 39.0 (37.0-40.9) | 36.4 (34.2-38.5) | .56 | .17 |
| Insomnia (WHIIRSe) | 9.6 (9.1-10.1) | 10.1 (9.6-10.7) | 9.6 (9.1-10.1) | 9.2 (8.7-9.8) | .03 | .20 |
| Depression (PHQf) | 7.7 (7.0-8.3) | 7.1 (6.4-7.7) | 6.5 (5.9-7.1) | 6.1 (5.4-6.7) | .69 | .19 |
| Fruit/vegetable intake, times/week | 22.7 (21.4-24.1) | 23.2 (21.7-24.7) | 24.3 (23.1-25.6) | 25.9 (24.6-27.3) | .24 | .21 |
| Strenuous or moderate aerobic exercise, min/week | 86.0 (72.3-99.7) | 96.2 (79.9-112) | 106 (91.1-120) | 137 (119-155) | .45 | .29 |
| Strenuous aerobic exercise, min/week | 29.0 (22.5-35.5) | 28.9 (21.8-36.0) | 32.0 (25.5-38.5) | 50.8 (40.7- 60.9) | .01 | .36 |
| Moderate aerobic exercise, min/week | 37.0 (30.9-43.2) | 45.3 (37.5-53.0) | 49.0 (42.2-55.7) | 54.1 (46.5- 61.7) | .49 | .10 |
| Mild aerobic exercise, min/week | 58.9 (51.5-66.2) | 65.0 (56.5-73.6) | 56.1 (48.9-63.3) | 74.1 (64.2-84.1) | .28 | .10 |
| Stretching min/week | 25.9 (21.3-30.4) | 24.7 (20.0-29.5) | 30.5 (25.1-35.8) | 45.7 (38.1-53.4) | .01 | .12 |
aAdjusted for age, race, sex, marital status, smoking status, education, years since diagnosis, site of cancer diagnosis, cancer stage. For outcomes of fatigue, insomnia, depression, and fruit/vegetable intake, means and 95% CIs were computed on the predicted values from the model. For outcomes of physical activity, means and 95% CIs were computed on the back-transformed predicted values (Y4-1), where Y represented the predicted values from the model.
bTreatment effect was assessed by the F test of the fixed 2-way interaction parameter for time and condition group.
cCalculated by taking the differences of the means at 6 months predicted from the model, including adjustment factors, divided by the standard deviation for the difference computed from the within and between subject variance components.
dBFI: Brief Fatigue Inventory
eWHIIRS: Women’s Health Initiative Insomnia Rating Scale
fPHQ: Patient Health Questionnaire